Companies · BAX
Baxter International
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 29, 2026
Baxter Q3 2026: Revenue grows 5% to $2.98B as FDA Warning Letter on Round Lake facility and ongoing Novum LVP hold define the risk landscape
Baxter International posted Q3 2026 net sales of $2.98 billion, up 5% year-over-year at actual rates and 5% on an organic basis, with both segments delivering growth — Medical Products & Therapies at 6% and Healthcare Systems & Technologies at 4%. The operating picture is overshadowed by two concurrent FDA enforcement actions: a September 2026 Warning Letter for the Round Lake, Illinois sterile injectable facility and the continued U.S./Canada distribution hold on the Novum LVP, with no timeline disclosed for resolution of either. Net income from continuing operations recovered sharply to $298 million in Q3 2026 versus a loss of $51 million in Q3 2025, driven primarily by a $253 million gain on early debt extinguishment rather than underlying operating improvement, while the adjusted gross margin ratio actually contracted 1.1 percentage points versus prior year.
Tone: mixedRevenue
$11.2B
BAX 10-K · FY 2025
Employees
37,500
Revenue growth YoY
+6%
Founded
1931
Profile
BAX 10-K Item 1 · Feb 12, 2026Baxter International is a global medical technology company that develops, manufactures and sells a broad portfolio of essential healthcare products including IV solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, smart bed systems, and patient monitoring technologies. Products are sold to hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, physicians and home patients in over 100 countries. Following the January 2025 divestiture of its Kidney Care business, Baxter operates three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Read filing description ↓ Collapse description ↑
Baxter International Inc., through our subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. As of December 31, 2025, after giving effect to the sale of our Kidney Care business, we manufactured products in over 20 countries and sold them in over 100 countries. Our business is currently comprised of three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our innovation strategy is focused on accelerating our sales growth through the introduction of new customer centric connected care and core therapy offerings. Connected care offerings include devices or software that can digitally connect, communicate and/or analyze data to help transform healthcare and improve patient outcomes. Our strategy also involves active portfolio management in the interest of maximizing value for Baxter stockholders and best positioning Baxter for long-term success, consistent with our profitability objectives.
Primary products
- sterile intravenous (IV) solutions
- infusion systems and devices
- parenteral nutrition therapies
- inhaled anesthetics
- generic injectable pharmaceuticals
- surgical hemostat and sealant products
Business segments
End markets
Geographies
Named customers
Segments of our business are significantly dependent on major contracts with GPOs, IDNs, and certain other distributors and purchasers.
“Our businesses benefit from a number of competitive advantages, including the breadth and depth of our product offerings and our strong relationships with customers, including hospitals and clinics, GPOs, IDNs, physicians and patients, many of whom self-administer home-based therapies that we supply.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Global net sales totaled $11.24 billion in 2025, an increase of 6% over 2024 on a reported basis and 3% on an operational sales basis.
The rest of BAX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.